Published • loading... • Updated
NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
The FDA backed the trial design and batch-testing plan, while NeuroScientific said StemSmart’s earlier study showed a 78% response rate.
Summary by Sydney Morning Herald
4 Articles
4 Articles
Sydney Morning Herald+3 Reposted by 3 other sources
NeuroScientific Biopharmaceuticals clears key US Crohn’s trial hurdle
NeuroScientific Biopharmaceuticals has landed key US backing for its Phase 2 stem cell Crohn’s trial, green-lighting a planned year-end start subject to final preparations.
·North Sydney, Australia
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left3Leaning Right1Center0Last UpdatedBias Distribution75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium
